7 October 2024 India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative.
The European Commission (EC) has approved Libtayo (cemiplimab) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with ≥1% PD-L1 expression, US biotech firm Regeneron revealed today. 29 March 2023
Karen Harrison has been named chief operating officer of the Therapeutics Division at Avacta, a UK-based life sciences company developing targeted oncology drugs and diagnostics. 29 March 2023
Shares US biotech Bicycle Therapeutics closed up more than 11% at $22.40 yesterday, after it revealed a licensing deal that could earn it as much as $1.7 billion. 29 March 2023
Results presented at the Society of Gynecologic Oncology (SGO) annual meeting have put two PD-1 inhibitors on course for a battle in the advanced endometrial cancer space. 29 March 2023
US clinical-stage biopharma company Viking Therapeutics saw its shares close up nearly 70% at $15.44 yesterday, after it released encouraging early-stage data on its obesity candidate VK2735. 29 March 2023
Covant Therapeutics, a Boston, USA-based covalent drug discovery company that was incubated by Roivant Sciences, has entered into an exclusive research collaboration and worldwide licensing agreement with German family-owned pharma major Boehringer Ingelheim covering Covant’s ADAR1 program. 29 March 2023
Russia will allow domestic drugmakers to develop generics of original foreign drugs under patent protection only in case of exodus of their producers from the Russian market. 29 March 2023
Bristol Myers Squibb’s Sotyktu (deucravacitinib) is continuing to vindicate the company’s decision to favor the drug’s development over Otezla (apremilast). 28 March 2023
Having won approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in September last year, Astra-Zeneca’s biologic Tezspire (tezepelumab) has now received backing from the health technology assessor. 28 March 2023
US regulatory T cell-focused Sonoma Biotherapeutics and Regeneron have joined forces to apply their scientific and clinical expertise and respective technology platforms to the discovery, development and commercialization of novel regulatory T cell (Treg) therapies for autoimmune diseases. 28 March 2023
Shares of USA/Israel-based biotech BrainStorm Cell Therapeutics rose as much as 13% yesterday on more positive news from the US regulator, which in February issued a refusal-to-file (RTF) letter regarding the submission for its cell therapy NurOwn (autologous MSC-NTF cells). 28 March 2023
Netherlands-based iOnctura today announced that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, a potential treatment for metastatic uveal melanoma by the UK’s Medicines & Healthcare products Regulatory Agency (MHRA). 28 March 2023
New Zealand-based AFT Pharmaceuticals has announced it has signed further new licence agreements for the intravenous dose form of its Maxigesic pain relief medicine as it continues to build momentum in its international business. 28 March 2023
Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, welcomes the announcement by the government of Newfoundland and Labrador that it is implementing a “switching” or transitioning policy to expand the use of biosimilar biologic medicines for its public drug program. 28 March 2023
Cancer immunotherapies and predictive biomarkers company Jounce Therapeutics has agreed to be acquired by Concentra Biosciences for $1.85 in cash per share plus a non-tradeable contingent value right (CVR). 27 March 2023
US rare diseases focused biotech Amicus Therapeutics today announced that the European Commission (EC) has granted approval for Pombiliti (cipaglucosidase alfa), a long-term enzyme replacement therapy (ERT) used in combination with miglustat for adults with late-onset Pompe disease (LOPD). 27 March 2023
German pain specialist Grünenthal is continuing its upwards trajectory, with its 2022 full-year results showing record revenue and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA). 27 March 2023
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024